Evidence map›Paper›PMID 28212535›Full record

ArticleOncotarget2017

Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.

Jessica Howell, David J Pinato, Ramya Ramaswami, Tadaaki Arizumi, Carlotta Ferrari, Antonello Gibbin, Michela E Burlone, Giulia Guaschino, Pierluigi Toniutto, James Black and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Observational
  11. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.Liver international : official journal of the International Association for the Study of the Liver · 2020
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Jessica HowellDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Ramya RamaswamiDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Tadaaki ArizumiDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
Carlotta FerrariDepartment of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
Antonello GibbinDepartment of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
Michela E BurloneDepartment of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
Giulia GuaschinoDepartment of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
Pierluigi ToniuttoDepartment of Experimental and Clinical Medicine, University of Udine, Udine, Italy.
James BlackDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Laura SellersDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
Mario PirisiDepartment of Translational Medicine, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara, Italy.
Rohini SharmaDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITHammersmith Hospital · GBKindai University · JPImperial College London · GBUniversity of Melbourne · AUUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsResponse to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy.

results442 patients with advanced stage HCC on sorafenib were recruited (follow-up 5096 person-months at risk). 88% had BCLC stage B or greater HCC and 72.3% had Child-Pugh A cirrhosis. On Cox multivariate regression, previously-treated HCC (HR 0.579, 95% CI 0.385-0.872, p=0.009), Cancer of Liver Italian Program (CLIP) score (HR 1.723, 95% CI 1.462-2.047, p<0.0001), baseline red cell distribution width (RDW; HR 1.234, 95% CI 1.115-1.290, p<0.0001) and neutrophil to lymphocyte ratio (NLR; HR 1.218, 95% CI 1.108-1.322, p<0.0001) were significant independent risks for shorter survival, whilst sorafenib-related diarrhoea was associated with prolonged survival (HR 0.533, 95% CI 0.373-0.763, p=0.001). The combination of RD-CLIP score (CLIP score multiplied by RDW) ≥ 70 and no treatment-related diarrhoea had good utility for predicting 3-month survival (AUC of 0.808 (95% CI 0.734-0.882), positive predictive value of 86.4% and negative predictive value of 83.3%), compared with CLIP (AUC=0.642) or BCLC score alone (AUC=0.579). RD-CLIP score ≥ 35 and no treatment-related diarrhoea had an AUC of 0.787 for predicting 12-month survival.

methodsPatients with HCC were consecutively recruited from three tertiary centres (Japan, Italy and UK) and clinical data were prospectively collected. The primary study endpoint was overall survival (OS) after commencing sorafenib.

conclusionThe novel prognostic index of CLIP score combined with inflammatory marker RDW and treatment-related diarrhoea has good accuracy for predicting overall, 3 month and 12 month survival in patients on sorafenib.

Indexed as

AgedAntineoplastic AgentsBiomarkersCarcinoma, HepatocellularFemaleFollow-Up StudiesHumansInflammationLiver NeoplasmsLymphocytesMaleMiddle AgedNeoplasm StagingNeutrophilsNiacinamidePhenylurea CompoundsAntineoplastic AgentsBiomarkersNiacinamidePhenylurea CompoundsSorafenibBCLCCLIP scoreinflammationliver cancerVEGF inhibitor

Identifiers

PMID28212535
PMCPMC5482646
OpenAlexW2588594032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.